Figure 4
From: Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways
In vitro effect of Claudin-5 expression on and in vivo tumor development of MDA-MB-231 cells. (a) The cell growth of MDACl5exp and MDACL5rib2 did not show any significant difference when compared to MDApEF6 (mean ± SD, n = 3). (b) The adhesive capacity of MDACL5rib2 was significantly decreased in comparison with the control MDApEF6 (p ≤ 0.001) (mean ± SD, n = 3). (c) The invasive capacity of MDACl5exp and MDACL5rib2 did not show any significant difference when compared to MDApef6 (mean ± SD, n = 3). (d) There were no significant differences in tumor growth over 33 day period (p = 0.29). (e) A significant increase was seen in TER of MDACL5rib2 over a period of 4 hours when compared to the control (p ≤ 0.001) (mean±SD, n = 3). (f) Effect of Claudin-5 on transepithelial resistance on MDA-MB-231 cells after treatment with HGF showed significant decreases in TER in control cells MDApEF6 over a period of 4 hours when compared to the untreated cells (using ANOVA p ≤ 0.05 versus respective untreated cells) (mean±SD, n = 3). (g) Significant decreases in TER were also seen in the transfected cells MDA CL5exp after treatment with HGF (using ANOVA p ≤ 0.05 versus respective untreated cells) (mean±SD, n = 3) and in MDA CL5rib2 (h) (using ANOVA p ≤ 0.05versus respective untreated cells) (mean±SD, n = 3).